How to Evaluate Research Peptide Suppliers

A Certificate of Analysis (COA) is a batch-specific laboratory document reporting a peptide's identity, purity, and content as measured by methods such as HPLC and mass spectrometry. Because synthesis quality varies between suppliers and between batches, the COA is the primary evidence that a research peptide is what it claims to be — and reproducible experiments depend on it.

Why Peptide Quality Varies

Most research peptides are produced by solid-phase peptide synthesis (SPPS), in which the chain is assembled one residue at a time on a resin support through repeated deprotection–coupling cycles. No coupling step runs at 100% efficiency, so the crude product is always a mixture of the target sequence and process-related impurities. How much of that mixture survives preparative HPLC purification and lyophilization — and how honestly the result is documented — is what distinguishes one batch from another.

Truncation and deletion sequences

When a coupling or deprotection step fails, chains either terminate early (truncation) or continue with one residue missing (deletion). These byproducts are structurally similar to the target and difficult to remove completely; analytical work on pharmaceutical peptides lists amino acid substitutions and chain cleavages among the impurity classes that reversed-phase QC methods must resolve (PMID 36871316). FDA's guidance for generic synthetic peptides requires identification of every peptide-related impurity present at 0.10% or more of the drug substance (FDA, ANDAs for Certain Highly Purified Synthetic Peptide Drug Products).

Racemization (D-amino acid isomers)

Activation of amino acids during coupling can convert L-residues to their D-form. These epimers have identical molecular mass and nearly identical chromatographic behavior, which makes them the hardest impurity class to detect: characterizing low-level D-Ser8, D-His1, and D-Asp9 isomeric impurities in synthetic semaglutide required offline fraction collection, chiral derivatization, and high-resolution tandem mass spectrometry (PMID 36462248). A routine HPLC-UV purity check does not see them.

Counterions and water: net peptide content vs gross weight

Purification on trifluoroacetic acid (TFA)-containing mobile phases leaves the peptide as a TFA salt, and lyophilized powder retains residual water. The mass in the vial is therefore not all peptide. When metrologists at Canada's National Research Council assigned purity to an angiotensin II certified reference material, the TFA counterion alone accounted for nearly 25% of the mass and the final peptide content was 691 ± 9 mg/g (PMID 30143839). A vial labeled "5 mg" states gross weight — the actual peptide mass (the net peptide content) is lower, sometimes substantially.

Reading a Certificate of Analysis

A COA condenses several distinct measurements into one document. Each answers a different question, and none of them is interchangeable with the others.

HPLC purity — what "≥98%" means

The headline number on most COAs is purity by reversed-phase HPLC: the target peak's area as a percentage of total peak area at the detection wavelength (typically ~214–220 nm, where peptide bonds absorb). "≥98%" means at most 2% of UV-absorbing material elutes as other peaks. Two caveats apply. First, the result is method-dependent — column, mobile-phase modifier, and temperature all change the measured purity, which is why a COA should state its method parameters (PMID 26397208). Second, area-% purity can conceal co-eluting impurities: a peak that integrates as one species can contain unresolved compounds, which is why pharmaceutical laboratories apply two-dimensional LC-MS to assess peak purity (PMID 36871316).

Mass spectrometry: identity, not purity

A COA should pair the chromatogram with mass-spectrometric identity confirmation: the observed molecular mass (for ESI, the deconvoluted neutral mass or the protonation envelope) should match the theoretical mass of the target sequence within the instrument's tolerance. MS establishes that the main peak is the right molecule; it does not quantify the impurities around it. A COA reporting MS without HPLC, or HPLC without MS, is incomplete.

Net peptide content vs purity — the classic confusion

Purity asks: of the peptide-related material, how much is the target sequence? Net peptide content asks: of everything in the vial — peptide, water, TFA counterions, residual salts — how much is peptide at all? A sample can be 99% pure by HPLC yet only ~70% peptide by mass, as in the angiotensin II reference material above. Experiments dosed by gross vial weight without a content correction inherit that error, and comparing results across suppliers without it is unreliable.

What a legitimate COA looks like

  • A batch/lot number that matches the number printed on the vial received
  • A test date and the identity of the laboratory or analyst
  • Method parameters — column, gradient, detection wavelength, MS mode — ideally with the actual chromatogram and spectrum attached
  • Identity (MS) and purity (HPLC) reported together, plus net peptide content where a content claim is made
  • For third-party documents, the testing laboratory's accreditation status (ISO/IEC 17025)

Third-Party Testing

An in-house COA is produced by the same organization that sells the peptide. Third-party testing sends material from the batch to an independent laboratory with no financial stake in the sale. The credential that matters for the testing lab is ISO/IEC 17025 accreditation — the international standard for competence of testing and calibration laboratories. Analytical methods developed to identify and quantify illegal peptide products seized by regulators have been validated using accuracy profiles based on the ISO 17025 guideline (PMID 28738623).

Common test methods

  • HPLC-UV — purity profiling; the standard method behind the percentage figure on a COA.
  • LC-MS / LC-MS/MS — identity confirmation of the main peak and identification of impurity masses.
  • Amino acid analysis (AAA) — quantifies constituent amino acids after hydrolysis; a classical route to net peptide content.
  • qNMR — absolute content assignment on the intact peptide without hydrolysis; used for reference-material-grade purity assignment (PMID 30143839).
  • Endotoxin (LAL assay) — screens for bacterial endotoxin, which matters when material enters cell-culture or animal experiments where endotoxin alone can produce experimental artifacts.

The research-chemical market justifies the skepticism. Lyophilized peptides under 5 kDa are among the most frequently encountered illegal biotechnology products and are readily sold online (PMID 28738623); analyses of seized falsified peptides have documented the wrong active ingredient, the wrong dosage, or no active ingredient at all (PMID 30165334). Independent verification is the one quality control the receiving laboratory performs directly.

Quality Red Flags

No single item below proves a product is substandard, but each removes a layer of verifiability that quality material does not need to hide behind.

  • No batch-specific COA. A supplier that cannot produce documentation for the specific batch shipped offers no evidence of identity or purity at all.
  • Generic or stock COAs. One undated document reused across every product and every restock, with no batch number, is marketing material rather than analytical data.
  • Purity-only reporting. An HPLC percentage with no mass-spectrometric identity confirmation: a purity number says nothing about which molecule is pure.
  • Missing net-content data. Dosing by gross vial weight assumes 100% content. Without a stated net peptide content (or, at minimum, the salt form), the actual peptide mass is unknown.
  • Inconsistent batch numbers. The COA batch number does not match the vial, or the same batch number persists across clearly separate restocks.
  • "For human use" marketing language. Dosing schedules, injection instructions, or therapeutic claims indicate an unapproved drug being marketed illegally; FDA determines intended use from the totality of a vendor's marketing, not from disclaimer labels. See Peptide Legality & Regulatory Status.
  • Price far below synthesis cost. Resin, protected amino acids, coupling reagents, preparative HPLC, and lyophilization set a floor on production cost. A long peptide priced below that floor implies corners were cut in synthesis, purification, or testing.

Storage and Handling as a Quality Variable

Quality measured at the supplier is only preserved if the material is handled correctly afterward. Lyophilized peptides are typically shipped dry and stored desiccated at -20°C; prolonged exposure to heat or humidity in transit — a broken cold chain — accelerates degradation before the vial is ever opened.

In laboratory workflows, reconstituted solutions are generally held at 4°C and used within days, with repeated freeze–thaw cycles avoided. Degradation rates are sequence-dependent: oxidation-prone residues (methionine, cysteine, tryptophan) and deamidation-prone motifs degrade fastest, so handling guidance valid for one peptide does not transfer automatically to another. For a compound-specific example of degradation pathways and storage data, see the research article on BPC-157 stability.

What This Means for Researchers

Supplier evaluation is an extension of experimental design: an irreproducible result traced to an impure or misidentified peptide is indistinguishable from a biological finding until the material itself is re-tested. The evaluation criteria on this page — batch-specific COAs, identity plus purity plus net content, ISO/IEC 17025-accredited third-party testing, and intact cold-chain handling — apply to research-use-only material. Nothing here is purchasing advice, and no supplier is named, ranked, or recommended.

All content on Peptpedia is provided for educational and research purposes only. For the research profiles of compounds discussed in this context, see BPC-157, TB-500, and ipamorelin.

Frequently Asked Questions

What is a COA for peptides?

A Certificate of Analysis (COA) is a batch-specific document in which a manufacturer or testing laboratory reports the results of analytical testing on one production batch of a peptide. For research peptides, a COA typically reports identity (confirmed by mass spectrometry), purity (measured by HPLC), and sometimes net peptide content. A legitimate COA names the batch number, the test date, the methods used, and the laboratory that performed the work.

What's the difference between purity and net peptide content?

Purity (usually reported from HPLC) measures how much of the peptide-related material in a vial is the target sequence rather than related impurities such as truncated or deletion sequences. Net peptide content measures how much of the vial's total mass is peptide at all — the remainder is typically water, counterions such as trifluoroacetate (TFA), and residual salts. A vial can be 99% pure by HPLC yet contain only about 70% peptide by mass: in one metrology study of an angiotensin II reference material, the TFA counterion alone accounted for nearly 25% of the mass.

What purity should a research peptide have?

For most in vitro and animal research, ≥95% HPLC purity with mass-spectrometric identity confirmation is a common baseline; quantitative binding or dose-response work typically calls for ≥98%. For context, FDA's guidance for generic synthetic peptides requires identification of every peptide-related impurity present at 0.10% or more of the drug substance. A purity figure alone is never sufficient — it should be accompanied by mass-spec identity and, ideally, net peptide content.

How do I verify a supplier's COA?

Check that the COA is batch-specific and that its batch number matches the label on the vial received, that it lists a test date and method parameters, and that it reports both HPLC purity and mass-spectrometric identity. Certificates issued by an independent laboratory accredited to ISO/IEC 17025 carry more evidentiary weight than in-house documents. The strongest verification is to send a sample from the received batch to an independent analytical laboratory for confirmatory HPLC-MS testing.

What is third-party testing?

Third-party testing means a batch is analyzed by an independent laboratory with no financial relationship to the supplier, rather than by the supplier's own in-house QC lab. The key credential to look for is ISO/IEC 17025 accreditation, the international standard for the competence of testing and calibration laboratories. A third-party certificate should report the same core data as a good in-house COA: identity by mass spectrometry, purity by HPLC, and ideally net peptide content.

Does price indicate quality?

Only at the low end. Peptide synthesis has real floor costs — resin, protected amino acids, coupling reagents, preparative HPLC purification, and lyophilization — so a long peptide priced far below synthesis cost is a genuine red flag for diluted, substituted, or untested material. Above that floor, a higher price guarantees nothing: analyses of seized falsified peptides have documented wrong active ingredients, wrong dosages, and vials with no active ingredient at all. Documentation, not price, is the quality signal.

Sources & Further Reading

  • Stalmans S et al. Quality control of cationic cell-penetrating peptides. J Pharm Biomed Anal. 2016 — PMID 26397208
  • Stoll DR et al. A strategy for assessing peak purity of pharmaceutical peptides in reversed-phase chromatography methods using two-dimensional liquid chromatography coupled to mass spectrometry. Part II. J Chromatogr A. 2023 — PMID 36871316
  • Zhang B et al. Characterization of low-level D-amino acid isomeric impurities of semaglutide using liquid chromatography-high resolution tandem mass spectrometry. J Pharm Biomed Anal. 2023 — PMID 36462248
  • Melanson JE et al. Purity assignment for peptide certified reference materials by combining qNMR and LC-MS/MS amino acid analysis results: application to angiotensin II. Anal Bioanal Chem. 2018 — PMID 30143839
  • Janvier S et al. Analysis of illegal peptide drugs via HILIC-DAD-MS. Talanta. 2017 — PMID 28738623
  • Janvier S et al. Falsification of biotechnology drugs: current dangers and/or future disasters? J Pharm Biomed Anal. 2018 — PMID 30165334
  • FDA — ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin (final guidance for industry)

Last updated: July 2026